How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Atezolizumab with nab-paclitaxel for treating PD‑L1-positive, triple-negative, advanced breast cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about atezolizumab

Marketing authorisation indication

Atezolizumab (Tecentriq, Roche) 'in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TBNC) whose tumours have PD‑L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease'.

Dosage in the marketing authorisation

The recommended dose of atezolizumab is 840 mg administered by intravenous infusion. For each 28‑day cycle, atezolizumab is administered on days 1 and 15, and nab-paclitaxel is administered on days 1, 8, and 15.

Price

The list price for atezolizumab is £3,807.69 per 1,200 mg/20 ml vial (excluding VAT, BNF online, accessed September 2019).

The estimated average cost of a course of treatment (28 days) is £7,617.38 from list price.

The company has a commercial arrangement, which would have applied if the technology had been recommended. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.